Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Receivables: 2015-2024

Historic Receivables for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to $8.5 million.

  • Intellia Therapeutics' Receivables rose 24.80% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.4 million, marking a year-over-year decrease of 56.43%. This contributed to the annual value of $8.5 million for FY2024, which is 77.26% down from last year.
  • Latest data reveals that Intellia Therapeutics reported Receivables of $8.5 million as of FY2024, which was down 77.26% from $37.5 million recorded in FY2023.
  • Intellia Therapeutics' Receivables' 5-year high stood at $37.5 million during FY2023, with a 5-year trough of $2.1 million in FY2020.
  • Over the past 3 years, Intellia Therapeutics' median Receivables value was $8.5 million (recorded in 2024), while the average stood at $17.1 million.
  • As far as peak fluctuations go, Intellia Therapeutics' Receivables soared by 597.76% in 2023, and later crashed by 77.26% in 2024.
  • Over the past 5 years, Intellia Therapeutics' Receivables (Yearly) stood at $2.1 million in 2020, then rose by 0.05% to $2.1 million in 2021, then skyrocketed by 151.90% to $5.4 million in 2022, then soared by 597.76% to $37.5 million in 2023, then plummeted by 77.26% to $8.5 million in 2024.